---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-007076"
form_type: "8-K"
ticker: "UG"
cik: "0000101295"
company_name: "UNITED GUARDIAN INC"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:18:46.631324+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# United-Guardian Q3 revenue down 26% YoY; net income falls 69% to $0.06 EPS

## Summary
- Q3 2025 revenue $2.26M vs $3.06M in Q3 2024; net income $268K vs $865K.
- Nine-month revenue $7.58M (-22%); net income $1.46M (-47%); EPS $0.32 vs $0.60.
- Decline driven by reduced orders from ASI for cosmetic ingredients due to tariff/geopolitical issues.
- Pharmaceutical and medical sales rose 10% and 6% respectively in first nine months.
- Company advancing Renacidin formulary inclusion project to boost pharmaceutical revenue.

## SEC filing metadata
- accession: 0001171843-25-007076
- form_type: 8-K
- ticker: UG
- cik: 0000101295
- company_name: UNITED GUARDIAN INC
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/101295/000117184325007076/0001171843-25-007076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/101295/000117184325007076/f8k_110425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-007076
- JSON: https://secwatch.observer/filing/0001171843-25-007076.json
- Plain text: https://secwatch.observer/filing/0001171843-25-007076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.